<SEC-DOCUMENT>0000875320-26-000206.txt : 20260513
<SEC-HEADER>0000875320-26-000206.hdr.sgml : 20260513
<ACCEPTANCE-DATETIME>20260513160711
ACCESSION NUMBER:		0000875320-26-000206
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20260513
DATE AS OF CHANGE:		20260513
EFFECTIVENESS DATE:		20260513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERTEX PHARMACEUTICALS INC / MA
		CENTRAL INDEX KEY:			0000875320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043039129
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295837
		FILM NUMBER:		26973272

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		6173416393

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>s-82026plan.htm
<DESCRIPTION>S-8
<TEXT>
<html><head><title>S-8 2026 Plan</title></head><body><div style="background-color:#E4E4E4;font-family:Arial, sans-serif;word-wrap:break-word"><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:756pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div id="id84bc26fa09547ae9aee2fc91b318e02_1" style="position:absolute;top:63pt"></div><div style="line-height:5.41pt;position:absolute;top:63pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:184.31pt;position:absolute;white-space:pre">As filed with the Securities and Exchange Commission on May 13, 2026</font></div><div style="line-height:5.41pt;position:absolute;top:82.28pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:467.39pt;position:absolute;white-space:pre">Registration No. 333-</font></div><div style="line-height:10.83pt;position:absolute;top:111.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:16pt;font-style:normal;font-weight:bold;left:242.22pt;position:absolute;white-space:pre">UNITED STATES</font></div><div style="line-height:10.83pt;position:absolute;top:130.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:16pt;font-style:normal;font-weight:bold;left:133.82pt;position:absolute;white-space:pre">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:5.41pt;position:absolute;top:149.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:264.57pt;position:absolute;white-space:pre">Washington, D.C. 20549</font></div><div style="line-height:10.83pt;position:absolute;top:171.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:16pt;font-style:normal;font-weight:bold;left:268.46pt;position:absolute;white-space:pre">FORM S-8</font></div><div style="line-height:6.77pt;position:absolute;top:202.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:234.51pt;position:absolute;white-space:pre">REGISTRATION STATEMENT</font></div><div style="line-height:6.77pt;position:absolute;top:214.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:288.23pt;position:absolute;white-space:pre">UNDER</font></div><div style="line-height:6.77pt;position:absolute;top:226.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:232.7pt;position:absolute;white-space:pre">THE SECURITIES ACT OF 1933</font></div><div style="line-height:10.83pt;position:absolute;top:262.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:16pt;font-style:normal;font-weight:bold;left:120.27pt;position:absolute;white-space:pre">VERTEX PHARMACEUTICALS INCORPORATED</font></div><div style="line-height:5.54pt;position:absolute;top:281.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:223.41pt;position:absolute;white-space:pre">(Exact name of registrant as specified in its charter)</font></div><div style="position:absolute;top:305.26pt;width:612pt"><div style="font-size:0pt;left:72pt;position:absolute;width:468.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:229.5pt"></td><td style="padding:0;width:9.75pt"></td><td style="padding:0;width:229.5pt"></td></tr><tr style="height:3pt"><td style="font-size:0;text-align:left;vertical-align:top" colspan="3"></td></tr><tr style="height:3pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:36pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:6pt;width:229.5pt"><div><div style="line-height:6.93pt;position:absolute;top:5.866pt;width:229.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:90.1pt;position:absolute;top:-2.101pt;white-space:pre">Massachusetts</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.39pt;position:absolute;top:-2.626pt;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:15.24pt;width:229.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:41.47pt;position:absolute;white-space:pre">(State or other jurisdiction of incorporation or </font></div><div style="line-height:5.54pt;position:absolute;top:27.24pt;width:229.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:93.43pt;position:absolute;white-space:pre">organization)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:239.25pt;position:absolute;top:6pt;width:229.5pt"><div><div style="line-height:6.93pt;position:absolute;top:16.046pt;width:229.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:95.42pt;position:absolute;top:-2.101pt;white-space:pre">04-3039129</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.07999999999998pt;position:absolute;top:-2.626pt;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:25.42pt;width:229.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:49.47pt;position:absolute;white-space:pre">(I.R.S. Employer Identification Number)</font></div></div></div></td></tr></table></div></div></div><div style="line-height:5.41pt;position:absolute;top:360.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:271.14pt;position:absolute;white-space:pre">50 Northern Avenue</font></div><div style="line-height:5.41pt;position:absolute;top:370.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:256.58pt;position:absolute;white-space:pre">Boston, Massachusetts 02210 </font></div><div style="line-height:5.54pt;position:absolute;top:379.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:240.73pt;position:absolute;white-space:pre">(Address of Principal Executive Offices)</font></div><div style="line-height:5.41pt;position:absolute;top:405.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:244.71pt;position:absolute;white-space:pre">2026 STOCK AND OPTION PLAN</font></div><div style="line-height:6.93pt;position:absolute;top:426.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:275.92pt;position:absolute;white-space:pre">(Full Title of Plan)</font></div><div style="line-height:5.41pt;position:absolute;top:444.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:267.92pt;position:absolute;white-space:pre">Reshma Kewalramani</font></div><div style="line-height:5.41pt;position:absolute;top:454.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:265.82pt;position:absolute;white-space:pre">Chief Executive Officer</font></div><div style="line-height:5.41pt;position:absolute;top:463.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:241.4pt;position:absolute;white-space:pre">Vertex Pharmaceuticals Incorporated</font></div><div style="line-height:5.41pt;position:absolute;top:473.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:271.14pt;position:absolute;white-space:pre">50 Northern Avenue</font></div><div style="line-height:5.41pt;position:absolute;top:483.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:256.58pt;position:absolute;white-space:pre">Boston, Massachusetts 02210</font></div><div style="line-height:5.41pt;position:absolute;top:492.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:281.01pt;position:absolute;white-space:pre">(617) 341-6100</font></div><div style="line-height:5.54pt;position:absolute;top:502.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:175.99pt;position:absolute;white-space:pre">(Name, address, and telephone number, including area code, of agent for service)</font></div><div style="line-height:5.54pt;position:absolute;top:522.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;white-space:pre">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller </font></div><div style="line-height:5.54pt;position:absolute;top:531.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting </font></div><div style="line-height:5.54pt;position:absolute;top:541.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="position:absolute;top:551.11pt;width:612pt"><div style="font-size:0pt;left:75.25pt;position:absolute;width:469.5pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:103.5pt"></td><td style="padding:0;width:103.5pt"></td><td style="padding:0;width:145.5pt"></td><td style="padding:0;width:117pt"></td></tr><tr style="height:5.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:5.25pt;width:103.5pt"><div><div style="line-height:6.93pt;position:absolute;top:6.296pt;width:103.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:10.89pt;position:absolute;top:-2.101pt;white-space:pre">Large accelerated filer </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:84.79pt;position:absolute;top:-2.626pt;white-space:pre">&#9746;</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:103.5pt;position:absolute;top:5.25pt;width:103.5pt"><div><div style="line-height:6.93pt;position:absolute;top:6.296pt;width:103.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:20.1pt;position:absolute;top:-2.101pt;white-space:pre">Accelerated filer </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.58pt;position:absolute;top:-2.626pt;white-space:pre">&#9744;</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:207pt;position:absolute;top:5.25pt;width:145.5pt"><div><div style="line-height:6.93pt;position:absolute;top:6.296pt;width:145.5pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:34pt;position:absolute;top:-2.101pt;white-space:pre">Non-accelerated filer </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.69pt;position:absolute;top:-2.626pt;white-space:pre">&#9744;</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:352.5pt;position:absolute;top:5.25pt;width:117pt"><div><div style="line-height:6.93pt;position:absolute;top:6.296pt;width:117pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:9.85pt;position:absolute;top:-2.101pt;white-space:pre">Smaller reporting company </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.33999999999999pt;position:absolute;top:-2.626pt;white-space:pre">&#9744;</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:352.5pt;position:absolute;top:19.5pt;width:117pt"><div><div style="line-height:6.93pt;position:absolute;top:6.296pt;width:117pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:9.84pt;position:absolute;top:-2.101pt;white-space:pre">Emerging growth company </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.34pt;position:absolute;top:-2.626pt;white-space:pre">&#9744;</font></div></div></div></td></tr></table></div></div></div><div style="background-color:#808080;border-color:#000000;border-style:solid;border-width:0.75pt;height:1.5pt;left:72pt;opacity:1;position:absolute;top:601.86pt;width:468pt;z-index:1"></div><div style="line-height:5.54pt;position:absolute;top:625.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with </font></div><div style="line-height:5.54pt;position:absolute;top:635.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div id="id84bc26fa09547ae9aee2fc91b318e02_121" style="position:absolute;top:72pt"></div><div style="line-height:6.77pt;position:absolute;top:72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:289.2pt;position:absolute;white-space:pre">PART I</font></div><div style="line-height:6.77pt;position:absolute;top:90pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:151.92pt;position:absolute;white-space:pre">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</font></div><div style="line-height:6.77pt;position:absolute;top:108pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 1. Plan Information.</font></div><div style="line-height:6.93pt;position:absolute;top:126pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">The documents containing the information specified in Part I of Form S-8 will be delivered to participants in </font></div><div style="line-height:6.93pt;position:absolute;top:138pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">the 2026 Stock and Option Plan (the &#8220;2026 Plan&#8221;) as specified by Rule 428(b)(1) of the Securities Act of 1933, as </font></div><div style="line-height:6.93pt;position:absolute;top:150pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">amended (the &#8220;Securities Act&#8221;).</font></div><div style="line-height:6.77pt;position:absolute;top:174pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 2. Registrant Information and Employee Plan Annual Information.</font></div><div style="line-height:6.93pt;position:absolute;top:194.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">The written statement required by Item 2 is included in documents sent or given to participants in the plan </font></div><div style="line-height:6.93pt;position:absolute;top:206.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.</font></div><div id="id84bc26fa09547ae9aee2fc91b318e02_134" style="position:absolute;top:236.09pt"></div><div style="line-height:6.77pt;position:absolute;top:236.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:287.26pt;position:absolute;white-space:pre">PART II</font></div><div style="line-height:6.77pt;position:absolute;top:254.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:149.29pt;position:absolute;white-space:pre">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</font></div><div style="line-height:6.77pt;position:absolute;top:284.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 3. Incorporation of Documents by Reference.</font></div><div style="line-height:6.93pt;position:absolute;top:304.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">The following documents filed by Vertex Pharmaceuticals Incorporated (the &#8220;Registrant&#8221;) with the Securities </font></div><div style="line-height:6.93pt;position:absolute;top:316.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">and Exchange Commission (the &#8220;SEC&#8221;) pursuant to the Securities Exchange Act of 1934, as amended (the </font></div><div style="line-height:6.93pt;position:absolute;top:328.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">&#8220;Exchange Act&#8221;), are incorporated by reference into this Registration Statement&#58;</font></div><div style="line-height:6.93pt;position:absolute;top:352.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">(a) The Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (including </font></div><div style="line-height:6.93pt;position:absolute;top:364.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">those portions of the Registrant&#8217;s definitive proxy statement for its 2026 annual meeting of shareholders </font></div><div style="line-height:6.93pt;position:absolute;top:376.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">incorporated by reference therein)&#59;</font></div><div style="line-height:6.93pt;position:absolute;top:400.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">(b) The Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026&#59;</font></div><div style="line-height:6.93pt;position:absolute;top:424.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">(c) The Registrant&#8217;s Current Reports on Form 8-K filed on March 31, 2026, April 29, 2026, and May 13, </font></div><div style="line-height:6.93pt;position:absolute;top:436.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">2026&#59;</font></div><div style="line-height:6.93pt;position:absolute;top:460.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">(d) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal </font></div><div style="line-height:6.93pt;position:absolute;top:472.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">year covered by the document referred to in (a) above&#59; and </font></div><div style="line-height:6.93pt;position:absolute;top:496.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">(e) The description of the Registrant&#8217;s common stock, filed as Exhibit 4.1 to the Form 10-K for the fiscal year </font></div><div style="line-height:6.93pt;position:absolute;top:508.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">ended December 31, 2025, which updates the description contained in the Registrant&#8217;s Registration Statement on </font></div><div style="line-height:6.93pt;position:absolute;top:520.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Form 8-A (filing date May 30, 1991), and as amended by any amendments or reports filed for the purpose of </font></div><div style="line-height:6.93pt;position:absolute;top:532.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">updating such description.</font></div><div style="line-height:6.93pt;position:absolute;top:556.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the </font></div><div style="line-height:6.93pt;position:absolute;top:568.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Exchange Act (other than Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K, </font></div><div style="line-height:6.93pt;position:absolute;top:580.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">including any exhibits included with such information, unless otherwise indicated therein), prior to the filing of a </font></div><div style="line-height:6.93pt;position:absolute;top:592.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all </font></div><div style="line-height:6.93pt;position:absolute;top:604.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement </font></div><div style="line-height:6.93pt;position:absolute;top:616.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">and to be a part hereof from the date of the filing of such documents.</font></div><div style="line-height:6.93pt;position:absolute;top:640.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall </font></div><div style="line-height:6.93pt;position:absolute;top:652.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement </font></div><div style="line-height:6.93pt;position:absolute;top:664.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by </font></div><div style="line-height:6.93pt;position:absolute;top:676.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be </font></div><div style="line-height:6.93pt;position:absolute;top:688.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div style="line-height:6.77pt;position:absolute;top:72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 4. Description of Securities.</font></div><div style="line-height:6.93pt;position:absolute;top:92.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:absolute;white-space:pre">Not applicable.</font></div><div style="line-height:6.77pt;position:absolute;top:112.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 5. Interests of Named Experts and Counsel.</font></div><div style="line-height:6.93pt;position:absolute;top:132.27pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:absolute;white-space:pre">Not applicable.</font></div><div style="line-height:6.77pt;position:absolute;top:152.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 6. Indemnification of Directors and Officers.</font></div><div style="line-height:6.93pt;position:absolute;top:172.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Section 2.02(b)(4) of the Massachusetts Business Corporations Act (the &#8220;MBCA&#8221;) provides that a </font></div><div style="line-height:6.93pt;position:absolute;top:184.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Massachusetts corporation may, in its articles of organization, eliminate or limit the personal liability of a director </font></div><div style="line-height:6.93pt;position:absolute;top:196.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">for monetary damages for breach of fiduciary duty notwithstanding any law to the contrary, except for liabilities </font></div><div style="line-height:6.93pt;position:absolute;top:208.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">involving (i) any breach of duty of loyalty to the corporation or to the shareholders, (ii) acts or omissions not in good </font></div><div style="line-height:6.93pt;position:absolute;top:220.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">faith, intentional misconduct or knowing violations of law, (iii) certain improper distributions or (iv) any transaction </font></div><div style="line-height:6.93pt;position:absolute;top:232.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">from which the director derived an improper personal benefit.</font></div><div style="line-height:6.93pt;position:absolute;top:256.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Section 8.51 of the MBCA authorizes a Massachusetts corporation to indemnify an individual who is a party </font></div><div style="line-height:6.93pt;position:absolute;top:268.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">to a proceeding because he or she is a director against liability incurred in the proceeding if (1) (i) such individual </font></div><div style="line-height:6.93pt;position:absolute;top:280.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">conducted himself&#47;herself in good faith, (ii) such individual reasonably believed that his&#47;her conduct was in the best </font></div><div style="line-height:6.93pt;position:absolute;top:292.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">interests of the corporation or that his&#47;her conduct was at least not opposed to the best interests of the corporation, </font></div><div style="line-height:6.93pt;position:absolute;top:304.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">and (iii) in the case of any criminal proceeding, such individual had no reasonable cause to believe that his&#47;her </font></div><div style="line-height:6.93pt;position:absolute;top:316.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">conduct was unlawful or (2) such individual engaged in conduct for which he or she shall not be liable under a </font></div><div style="line-height:6.93pt;position:absolute;top:328.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">provision of the articles of organization authorized by Section 2.02(b)(4) of the MBCA.</font></div><div style="line-height:6.93pt;position:absolute;top:352.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Section 8.52 of the MBCA provides that a corporation must indemnify a director who is wholly successful, on </font></div><div style="line-height:6.93pt;position:absolute;top:364.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">the merits or otherwise, in the defense of any proceeding to which the director was a party because he or she was a </font></div><div style="line-height:6.93pt;position:absolute;top:376.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">director of the corporation against reasonable expenses incurred by him or her in connection with the proceeding.</font></div><div style="line-height:6.93pt;position:absolute;top:400.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Section 8.56 of the MBCA authorizes a corporation to indemnify an officer of the corporation who is a party </font></div><div style="line-height:6.93pt;position:absolute;top:412.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">to a proceeding because he or she is an officer of the corporation to the same extent as a director and, if he or she is </font></div><div style="line-height:6.93pt;position:absolute;top:424.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">an officer but not a director, to such further extent as may be provided by the articles of organization, by-laws or a </font></div><div style="line-height:6.93pt;position:absolute;top:436.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">resolution of the board of directors or contract, except for liability arising out of acts or omissions not in good faith </font></div><div style="line-height:6.93pt;position:absolute;top:448.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">or which involve intentional misconduct or a knowing violation of law. Section 8.56 of the MBCA requires that a </font></div><div style="line-height:6.93pt;position:absolute;top:460.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Massachusetts corporation indemnify an officer of the corporation who was wholly successful, on the merits or </font></div><div style="line-height:6.93pt;position:absolute;top:472.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">otherwise, in the defense of any proceeding to which such officer was a party because he or she was an officer of the </font></div><div style="line-height:6.93pt;position:absolute;top:484.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">corporation.</font></div><div style="line-height:6.93pt;position:absolute;top:508.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Part D of Article VI of the Restated Articles of Organization of the Registrant provides that no director of the </font></div><div style="line-height:6.93pt;position:absolute;top:520.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Registrant shall be personally liable to the Registrant or its shareholders for monetary damages for any breach of </font></div><div style="line-height:6.93pt;position:absolute;top:532.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">fiduciary duty as a director. Such paragraph provides further, however, that to the extent provided by applicable law </font></div><div style="line-height:6.93pt;position:absolute;top:544.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">it will not eliminate or limit the liability of a director (i) for any breach of the director&#8217;s duty of loyalty to the </font></div><div style="line-height:6.93pt;position:absolute;top:556.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Registrant or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or </font></div><div style="line-height:6.93pt;position:absolute;top:568.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">a knowing violation of law, (iii) under Section 61 or 62 of the Massachusetts Business Corporation Law, or (iv) for </font></div><div style="line-height:6.93pt;position:absolute;top:580.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">any transactions from which the director derived an improper personal benefit.</font></div><div style="line-height:6.93pt;position:absolute;top:604.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Article V of the Registrant&#8217;s Amended and Restated By-laws provides that the Registrant shall indemnify, and </font></div><div style="line-height:6.93pt;position:absolute;top:616.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">advance funds to pay for or reimburse the reasonable expenses incurred by, its directors and the officers that have </font></div><div style="line-height:6.93pt;position:absolute;top:628.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">been appointed by the Board of Directors (including persons who serve at the Registrant&#8217;s request as a director, </font></div><div style="line-height:6.93pt;position:absolute;top:640.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">officer, or trustee of another organization in which the Registrant has any interest, direct or indirect, as a </font></div><div style="line-height:6.93pt;position:absolute;top:652.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">shareholder, creditor, or otherwise or who serve at the Registrant&#8217;s request in any capacity with respect to any </font></div><div style="line-height:6.93pt;position:absolute;top:664.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">employee benefit plan) to the fullest extent permitted by law, and may indemnify, and advance funds to pay for or </font></div><div style="line-height:6.93pt;position:absolute;top:676.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">reimburse the reasonable expenses incurred by, such other employees and agents as are identified by the Board of </font></div><div style="line-height:6.93pt;position:absolute;top:688.45pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Directors.</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div style="line-height:6.93pt;position:absolute;top:72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.5pt;position:absolute;white-space:pre">Article V of the Registrant&#8217;s Amended and Restated By-laws gives the Board of Directors of the Registrant </font></div><div style="line-height:6.93pt;position:absolute;top:84pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">the power to authorize the purchase and maintenance of insurance, in such amounts as the Board of Directors may </font></div><div style="line-height:6.93pt;position:absolute;top:96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">from time to time deem appropriate, on behalf of any person who is or was a director, officer, or agent of the </font></div><div style="line-height:6.93pt;position:absolute;top:108pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Registrant, or who is or was serving at the request of the Registrant as a director, officer or agent of another </font></div><div style="line-height:6.93pt;position:absolute;top:120pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">organization in which the Registrant has any interest, direct or indirect, as a shareholder, creditor or otherwise, or </font></div><div style="line-height:6.93pt;position:absolute;top:132pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">with respect to any employee benefit plan, against any liability incurred by such person in any such capacity, or </font></div><div style="line-height:6.93pt;position:absolute;top:144pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">arising out of such person&#8217;s status as such agent, whether or not such person is entitled to indemnification by the </font></div><div style="line-height:6.93pt;position:absolute;top:156pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Registrant pursuant to Article V or otherwise and whether or not the Registrant would have the power to indemnify </font></div><div style="line-height:6.93pt;position:absolute;top:168pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">the person against such liability.</font></div><div style="line-height:6.77pt;position:absolute;top:192pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 7. Exemption from Registration Claimed.</font></div><div style="line-height:6.93pt;position:absolute;top:212.09pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.75pt;position:absolute;white-space:pre">Not applicable.</font></div><div id="id84bc26fa09547ae9aee2fc91b318e02_91" style="position:absolute;top:232.18pt"></div><div style="line-height:6.77pt;position:absolute;top:232.18pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 8. Exhibits.</font></div><div style="position:absolute;top:262.78pt;width:612pt"><div style="font-size:0pt;left:75.25pt;position:absolute;width:464.25pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:38.25pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:159pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:48.75pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:60.75pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:59.25pt"></td><td style="padding:0;width:9pt"></td><td style="padding:0;width:48.75pt"></td><td style="padding:0;width:4.5pt"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top" colspan="12"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:50.25pt"><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:31.5pt;width:38.25pt"><div><div style="line-height:5.41pt;position:absolute;top:33.62pt;width:38.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Exhibit </font></div><div style="line-height:5.41pt;position:absolute;top:41.62pt;width:38.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Number</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:31.5pt;width:159pt"><div><div style="line-height:5.41pt;position:absolute;top:41.62pt;width:159pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:46.09pt;position:absolute;white-space:pre">Exhibit Description</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:31.5pt;width:48.75pt"><div><div style="line-height:5.41pt;position:absolute;top:12.82pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.72pt;position:absolute;white-space:pre">Filed </font></div><div style="line-height:5.41pt;position:absolute;top:22.42pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:9.61pt;position:absolute;white-space:pre">with this </font></div><div style="line-height:5.41pt;position:absolute;top:32.02pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:3.28pt;position:absolute;white-space:pre">Registration </font></div><div style="line-height:5.41pt;position:absolute;top:41.62pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.06pt;position:absolute;white-space:pre">Statement</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:273pt;position:absolute;top:31.5pt;width:60.75pt"><div><div style="line-height:5.41pt;position:absolute;top:3.22pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:7.73pt;position:absolute;white-space:pre">Incorporated </font></div><div style="line-height:5.41pt;position:absolute;top:12.82pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.07pt;position:absolute;white-space:pre">by Reference </font></div><div style="line-height:5.41pt;position:absolute;top:22.42pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.73pt;position:absolute;white-space:pre">herein from-</font></div><div style="line-height:5.41pt;position:absolute;top:32.02pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.05pt;position:absolute;white-space:pre">Form or </font></div><div style="line-height:5.41pt;position:absolute;top:41.62pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:15.06pt;position:absolute;white-space:pre">Schedule</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:absolute;top:31.5pt;width:59.25pt"><div><div style="line-height:5.41pt;position:absolute;top:41.62pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.64pt;position:absolute;white-space:pre">Filing Date</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:411pt;position:absolute;top:31.5pt;width:48.75pt"><div><div style="line-height:5.41pt;position:absolute;top:22.42pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:8.06pt;position:absolute;white-space:pre">SEC File&#47; </font></div><div style="line-height:5.41pt;position:absolute;top:32.02pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:16.71pt;position:absolute;white-space:pre">Reg. </font></div><div style="line-height:5.41pt;position:absolute;top:41.62pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:10.17pt;position:absolute;white-space:pre">Number</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:38.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:81.75pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:23.12pt;position:absolute;white-space:pre">4.1</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:81.75pt;width:159pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/a10k_2025-exhibit31.htm">Restated Articles of Organization of </a></font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/a10k_2025-exhibit31.htm">Vertex Pharmaceuticals Incorporated, </a></font></div><div style="line-height:6.93pt;position:absolute;top:26.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/a10k_2025-exhibit31.htm">as amended.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:273pt;position:absolute;top:81.75pt;width:60.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.1pt;position:absolute;white-space:pre">10-K </font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.84pt;position:absolute;white-space:pre">(Exhibit 3.1)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:absolute;top:81.75pt;width:59.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.08pt;position:absolute;white-space:pre">February 13, </font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:19.62pt;position:absolute;white-space:pre">2026</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:411pt;position:absolute;top:81.75pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.79pt;position:absolute;text-decoration:none;white-space:pre">000-19319</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:120pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:23.12pt;position:absolute;white-space:pre">4.2</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:120pt;width:159pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/a10k_2024-exhibit32.htm">Amended and Restated By-laws of </a></font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/a10k_2024-exhibit32.htm">Vertex Pharmaceuticals Incorporated.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:273pt;position:absolute;top:120pt;width:60.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.1pt;position:absolute;white-space:pre">10-Q </font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.84pt;position:absolute;white-space:pre">(Exhibit 3.2)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:absolute;top:120pt;width:59.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.08pt;position:absolute;white-space:pre">February 13, </font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:19.62pt;position:absolute;white-space:pre">2025</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:411pt;position:absolute;top:120pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.79pt;position:absolute;text-decoration:none;white-space:pre">000-19319</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:26.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:146.25pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:23.12pt;position:absolute;white-space:pre">4.3</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:146.25pt;width:159pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="https://www.sec.gov/Archives/edgar/data/875320/000087532018000009/a10k2017exhibit41.htm">Specimen stock certificate.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:273pt;position:absolute;top:146.25pt;width:60.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.1pt;position:absolute;white-space:pre">10-K </font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:60.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.84pt;position:absolute;white-space:pre">(Exhibit 4.1)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:342.75pt;position:absolute;top:146.25pt;width:59.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.08pt;position:absolute;white-space:pre">February 15, </font></div><div style="line-height:6.93pt;position:absolute;top:14.63pt;width:59.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:19.62pt;position:absolute;white-space:pre">2018</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:411pt;position:absolute;top:146.25pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.79pt;position:absolute;text-decoration:none;white-space:pre">000-19319</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:33.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:172.5pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:23.12pt;position:absolute;white-space:pre">5.1</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:172.5pt;width:159pt"><div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex51xopinion2026p.htm">Opinion of Ropes &#38; Gray LLP as to </a></font></div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:12.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex51xopinion2026p.htm">the legality of the shares being </a></font></div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:22.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex51xopinion2026p.htm">registered.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:172.5pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.76pt;position:absolute;white-space:pre">X</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:206.25pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:18.12pt;position:absolute;white-space:pre">23.1</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:206.25pt;width:159pt"><div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex231xeyconsent.htm">Consent of Ernst &#38; Young LLP.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:206.25pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.76pt;position:absolute;white-space:pre">X</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:220.5pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:18.12pt;position:absolute;white-space:pre">23.2</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:220.5pt;width:159pt"><div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex51xopinion2026p.htm">Consent of Ropes &#38; Gray LLP </a></font></div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:12.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex51xopinion2026p.htm">(included as part of Exhibit 5.1).</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:220.5pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.76pt;position:absolute;white-space:pre">X</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:33.75pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:243.75pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:18.12pt;position:absolute;white-space:pre">24.1</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:243.75pt;width:159pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="#id84bc26fa09547ae9aee2fc91b318e02_77">Power of Attorney to file future </a></font></div><div style="line-height:6.93pt;position:absolute;top:12.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="#id84bc26fa09547ae9aee2fc91b318e02_77">amendments (set forth on signature </a></font></div><div style="line-height:6.93pt;position:absolute;top:22.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="#id84bc26fa09547ae9aee2fc91b318e02_77">page of this Registration Statement).</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:243.75pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:48.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.76pt;position:absolute;white-space:pre">X</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:23.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:277.5pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:18.12pt;position:absolute;white-space:pre">99.1</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:277.5pt;width:159pt"><div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex9912026stockand.htm">Vertex Pharmaceuticals Incorporated </a></font></div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:12.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="a2026s-8_ex9912026stockand.htm">2026 Stock and Option Plan.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:277.5pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:12.67pt;width:48.75pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.76pt;position:absolute;text-decoration:none;white-space:pre">X</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:300.75pt;width:38.25pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:38.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.62pt;position:absolute;white-space:pre">107</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:47.25pt;position:absolute;top:300.75pt;width:159pt"><div><div style="font-size:12pt;line-height:6.93pt;position:absolute;top:2.63pt;width:159pt"><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.4pt;position:absolute;text-decoration:underline;white-space:pre"><a style="-sec-extract:exhibit;color:inherit;text-decoration:inherit;z-index:1" href="exfilingfees.htm">Filing Fee Table.</a></font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:215.25pt;position:absolute;top:300.75pt;width:48.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:48.75pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.76pt;position:absolute;text-decoration:none;white-space:pre">X</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr></table></div></div></div><div style="-sec-extract:summary;background-color:#808080;border-color:#000000;border-style:solid;border-width:0.75pt;height:1.5pt;left:72pt;opacity:1;position:absolute;top:594.78pt;width:468pt;z-index:1"></div><div id="id84bc26fa09547ae9aee2fc91b318e02_105" style="position:absolute;top:630.88pt"></div><div style="line-height:6.77pt;position:absolute;top:630.88pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:72pt;position:absolute;white-space:pre">Item 9. Undertakings.</font></div><div style="line-height:6.93pt;position:absolute;top:654.98pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;text-decoration:none;white-space:pre">(a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">The undersigned Registrant hereby undertakes&#58;</font></div><div style="line-height:6.93pt;position:absolute;top:679.08pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">(1)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">To file, during any period in which offers or sales are being made, a post-effective amendment to this </font></div><div style="line-height:6.93pt;position:absolute;top:691.08pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">Registration Statement&#58;</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div style="line-height:6.93pt;position:absolute;top:72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">To include any prospectus required by Section 10(a)(3) of the Securities Act&#59;</font></div><div style="line-height:6.93pt;position:absolute;top:96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">To reflect in the prospectus any facts or events arising after the effective date of the Registration </font></div><div style="line-height:6.93pt;position:absolute;top:108pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">Statement (or the most recent post-effective amendment thereof) which, individually or in the </font></div><div style="line-height:6.93pt;position:absolute;top:120pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">aggregate, represent a fundamental change in the information set forth in the Registration </font></div><div style="line-height:6.93pt;position:absolute;top:132pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered </font></div><div style="line-height:6.93pt;position:absolute;top:144pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">(if the total dollar value of securities offered would not exceed that which was registered) and any </font></div><div style="line-height:6.93pt;position:absolute;top:156pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">deviation from the low or high end of the estimated maximum offering range may be reflected in </font></div><div style="line-height:6.93pt;position:absolute;top:168pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the </font></div><div style="line-height:6.93pt;position:absolute;top:180pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">changes in volume and price represent no more than a 20% change in the maximum aggregate </font></div><div style="line-height:6.93pt;position:absolute;top:192pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration </font></div><div style="line-height:6.93pt;position:absolute;top:204pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">Statement.</font></div><div style="line-height:6.93pt;position:absolute;top:228pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">(iii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">To include any material information with respect to the plan of distribution not previously </font></div><div style="line-height:6.93pt;position:absolute;top:240pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">disclosed in the Registration Statement or any material change to such information in the </font></div><div style="line-height:6.93pt;position:absolute;top:252pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">Registration Statement&#59;</font></div><div style="line-height:6.94pt;position:absolute;top:276pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">provided, however</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.36pt;position:absolute;text-decoration:none;white-space:pre">, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the </font></div><div style="line-height:6.93pt;position:absolute;top:288pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">registration statement is on Form S-8, and the information required to be included in a post-</font></div><div style="line-height:6.93pt;position:absolute;top:300pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">effective amendment by those paragraphs is contained in reports filed with or furnished to the </font></div><div style="line-height:6.93pt;position:absolute;top:312pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that </font></div><div style="line-height:6.93pt;position:absolute;top:324pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144pt;position:absolute;text-decoration:none;white-space:pre">are incorporated by reference in this Registration Statement.</font></div><div style="line-height:6.93pt;position:absolute;top:348pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">(2)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">That, for the purpose of determining any liability under the Securities Act, each such post-effective </font></div><div style="line-height:6.93pt;position:absolute;top:360pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">amendment shall be deemed to be a new registration statement relating to the securities offered therein, and </font></div><div style="line-height:6.93pt;position:absolute;top:372pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="line-height:6.93pt;position:absolute;top:396pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">(3)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">To remove from registration by means of a post-effective amendment any of the securities being registered </font></div><div style="line-height:6.93pt;position:absolute;top:408pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre">which remain unsold at the termination of the offering.</font></div><div style="line-height:6.93pt;position:absolute;top:432pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;text-decoration:none;white-space:pre">(b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the </font></div><div style="line-height:6.93pt;position:absolute;top:444pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the </font></div><div style="line-height:6.93pt;position:absolute;top:456pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to </font></div><div style="line-height:6.93pt;position:absolute;top:468pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be </font></div><div style="line-height:6.93pt;position:absolute;top:480pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">deemed to be a new registration statement relating to the securities offered therein, and the offering of such </font></div><div style="line-height:6.93pt;position:absolute;top:492pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="line-height:6.93pt;position:absolute;top:516pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;text-decoration:none;white-space:pre">(c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers </font></div><div style="line-height:6.93pt;position:absolute;top:528pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has </font></div><div style="line-height:6.93pt;position:absolute;top:540pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">been advised that in the opinion of the Securities and Exchange Commission such indemnification is against </font></div><div style="line-height:6.93pt;position:absolute;top:552pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for </font></div><div style="line-height:6.93pt;position:absolute;top:564pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid </font></div><div style="line-height:6.93pt;position:absolute;top:576pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or </font></div><div style="line-height:6.93pt;position:absolute;top:588pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">proceeding) is asserted by such director, officer or controlling person in connection with the securities being </font></div><div style="line-height:6.93pt;position:absolute;top:600pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling </font></div><div style="line-height:6.93pt;position:absolute;top:612pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is </font></div><div style="line-height:6.93pt;position:absolute;top:624pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre">against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div style="line-height:6.77pt;position:absolute;top:72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:273.51pt;position:absolute;white-space:pre">SIGNATURES</font></div><div style="line-height:6.93pt;position:absolute;top:96.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;white-space:pre">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to </font></div><div style="line-height:6.93pt;position:absolute;top:108.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to </font></div><div style="line-height:6.93pt;position:absolute;top:120.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts on May 13, 2026.</font></div><div style="position:absolute;top:132.1pt;width:612pt"><div style="font-size:0pt;left:75.25pt;position:absolute;width:468.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:226.5pt"></td><td style="padding:0;width:36pt"></td><td style="padding:0;width:206.25pt"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top" colspan="3"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top" colspan="2"><div style="left:226.5pt;position:absolute;top:31.5pt;width:242.25pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:242.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">VERTEX PHARMACEUTICALS INCORPORATED</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top" colspan="2"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:226.5pt;position:absolute;top:61.5pt;width:36pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:36pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:absolute;top:61.5pt;width:206.25pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:206.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.92pt;position:absolute;white-space:pre">&#47;s&#47; Reshma Kewalramani</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:absolute;top:75.75pt;width:206.25pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:206.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.88pt;position:absolute;white-space:pre">Reshma Kewalramani</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:262.5pt;position:absolute;top:90pt;width:206.25pt"><div><div style="line-height:6.94pt;position:absolute;top:3.66pt;width:206.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:normal;left:27.13pt;position:absolute;white-space:pre">Chief Executive Officer and President</font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div id="id84bc26fa09547ae9aee2fc91b318e02_77" style="position:absolute;top:72pt"></div><div style="line-height:6.77pt;position:absolute;top:72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:249.37pt;position:absolute;white-space:pre">POWER OF ATTORNEY</font></div><div style="line-height:6.93pt;position:absolute;top:96.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;white-space:pre">Each person whose signature appears below constitutes and appoints Reshma Kewalramani, Joy Liu, and </font></div><div style="line-height:6.93pt;position:absolute;top:108.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Omar White, and each of them singly, his&#47;her true and lawful attorneys-in-fact and agents, with full power of </font></div><div style="line-height:6.93pt;position:absolute;top:120.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">substitution and resubstitution in each of them singly, for him&#47;her and in his&#47;her name, place and stead, and in any </font></div><div style="line-height:6.93pt;position:absolute;top:132.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration </font></div><div style="line-height:6.93pt;position:absolute;top:144.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">Statement on Form S-8 of Vertex Pharmaceuticals Incorporated, and to file the same, with all exhibits thereto and </font></div><div style="line-height:6.93pt;position:absolute;top:156.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-</font></div><div style="line-height:6.93pt;position:absolute;top:168.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing </font></div><div style="line-height:6.93pt;position:absolute;top:180.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">requisite or necessary to be done in or about the premises, as full to all intents and purposes as he might or could do </font></div><div style="line-height:6.93pt;position:absolute;top:192.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their </font></div><div style="line-height:6.93pt;position:absolute;top:204.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">substitute may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:6.93pt;position:absolute;top:228.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;white-space:pre">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the </font></div><div style="line-height:6.93pt;position:absolute;top:240.1pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:72pt;position:absolute;white-space:pre">following persons in the capacities and on the date indicated.</font></div><div style="position:absolute;top:252.1pt;width:612pt"><div style="font-size:0pt;left:75.25pt;position:absolute;width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:33pt"></td><td style="padding:0;width:144.75pt"></td><td style="padding:0;width:14.25pt"></td><td style="padding:0;width:191.25pt"></td><td style="padding:0;width:9.75pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top" colspan="6"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:12pt"><td style="font-size:0;text-align:left;vertical-align:top" colspan="2"><div style="position:absolute;top:31.5pt;width:177.75pt"><div><div style="line-height:5.41pt;position:absolute;top:3.37pt;width:177.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:72.22pt;position:absolute;white-space:pre">Signature</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:192pt;position:absolute;top:31.5pt;width:191.25pt"><div><div style="line-height:5.41pt;position:absolute;top:3.37pt;width:191.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:87.63pt;position:absolute;white-space:pre">Title</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393pt;position:absolute;top:31.5pt;width:75pt"><div><div style="line-height:5.41pt;position:absolute;top:3.37pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:8pt;font-style:normal;font-weight:bold;left:29.51pt;position:absolute;white-space:pre">Date</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:59.25pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:59.25pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.17pt;position:absolute;white-space:pre">&#47;s&#47; Reshma Kewalramani</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:59.25pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Chief Executive Officer, President and Director </font></div><div style="line-height:6.58pt;position:absolute;top:12.13pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">(Principal Executive Officer)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:59.25pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:73.5pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:28.13pt;position:absolute;white-space:pre">Reshma Kewalramani</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:18pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:103.5pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:103.5pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:7.42pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:21.45pt;position:absolute;white-space:pre">&#47;s&#47; Charles F. Wagner, Jr.</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:103.5pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Executive Vice President and Chief Operating </font></div><div style="line-height:6.58pt;position:absolute;top:12.13pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">&#38; Financial Officer (Principal Financial </font></div><div style="line-height:6.58pt;position:absolute;top:21.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Officer)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:103.5pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:121.5pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:29.69pt;position:absolute;white-space:pre">Charles F. Wagner. Jr.</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:151.5pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:151.5pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:26.3pt;position:absolute;white-space:pre">&#47;s&#47; Kristen C. Ambrose</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:151.5pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Senior Vice President and Chief Accounting </font></div><div style="line-height:6.58pt;position:absolute;top:12.13pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Officer (Principal Accounting Officer)</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:151.5pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:165.75pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:34.29pt;position:absolute;white-space:pre">Kristen C. Ambrose</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:195.75pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.5pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:195.75pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:30.48pt;position:absolute;white-space:pre">&#47;s&#47; Jeffrey M. Leiden</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:192pt;position:absolute;top:195.75pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Executive Chairman</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:393pt;position:absolute;top:195.75pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.5pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:210pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:38.25pt;position:absolute;white-space:pre">Jeffrey M. Leiden</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:240pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:240pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:27.99pt;position:absolute;white-space:pre">&#47;s&#47; Sangeeta N. Bhatia</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:240pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:240pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:254.25pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:35.88pt;position:absolute;white-space:pre">Sangeeta N. Bhatia</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:284.25pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:284.25pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:38.8pt;position:absolute;white-space:pre">&#47;s&#47; Lloyd Carney</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:284.25pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:284.25pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:298.5pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:46.14pt;position:absolute;white-space:pre">Lloyd Carney</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:328.5pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:328.5pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:41.58pt;position:absolute;white-space:pre">&#47;s&#47; Alan Garber</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:328.5pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:328.5pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:342.75pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:48.79pt;position:absolute;white-space:pre">Alan Garber</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:372.75pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:6.25pt;position:absolute;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:372.75pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:34.65pt;position:absolute;white-space:pre">&#47;s&#47; Michel Lagarde</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:372.75pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:372.75pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:387pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:42.21pt;position:absolute;white-space:pre">Michel Lagarde</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:417pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:417pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:32.43pt;position:absolute;white-space:pre">&#47;s&#47; Diana McKenzie</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:417pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:417pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:431.25pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:40.1pt;position:absolute;white-space:pre">Diana McKenzie</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr></table></div></div></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:720pt"><div style="width:468pt"></div></div><div style="position:absolute"><div style="width:468pt"></div></div><div><div style="position:absolute;top:72pt;width:612pt"><div style="font-size:0pt;left:75.25pt;position:absolute;width:468pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:33pt"></td><td style="padding:0;width:144.75pt"></td><td style="padding:0;width:14.25pt"></td><td style="padding:0;width:191.25pt"></td><td style="padding:0;width:9.75pt"></td><td style="padding:0;width:75pt"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:23.25pt;position:absolute;white-space:pre">&#47;s&#47; Nancy A. Thornberry</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:14.25pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:31.38pt;position:absolute;white-space:pre">Nancy A. Thornberry</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:44.25pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:44.25pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:37.41pt;position:absolute;white-space:pre">&#47;s&#47; Bruce I. Sachs</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:44.25pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:44.25pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:58.5pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:44.84pt;position:absolute;white-space:pre">Bruce I. Sachs</font></div></div></div></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:88.5pt;width:33pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:33pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">By&#58;</font></div></div></div></td><td style="border-bottom:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:88.5pt;width:144.75pt"><div><div style="line-height:6.93pt;position:absolute;top:3.67pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:29.09pt;position:absolute;white-space:pre">&#47;s&#47; Jennifer Schneider</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:192pt;position:absolute;top:88.5pt;width:191.25pt"><div><div style="line-height:6.58pt;position:absolute;top:2.63pt;width:191.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:4.75pt;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"></td><td style="font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="left:393pt;position:absolute;top:88.5pt;width:75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:9.59pt;position:absolute;white-space:pre">May 13, 2026</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:0.75pt solid #000000;font-size:0;text-align:left;vertical-align:top"><div style="left:33pt;position:absolute;top:102.75pt;width:144.75pt"><div><div style="line-height:6.58pt;position:absolute;top:4.12pt;width:144.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:36.93pt;position:absolute;white-space:pre">Jennifer Schneider</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:15.75pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr></table></div></div></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>exfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e1dd7-c299-762e-818a-a7f1d09f14e4,g:a0c1a596-6cae-4f2c-a3b5-733745d1981f,d:f23831f79c2648d983889312f23dda47-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ffd="http://xbrl.sec.gov/ffd/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exfilingfees</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-16">0000875320</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-17">VERTEX PHARMACEUTICALS INC / MA</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ffd:FeeExhibitTp" id="f-18">EX-FILING FEES</ix:nonNumeric><ix:nonNumeric contextRef="c-2" name="ffd:PrevslyPdFlg" id="f-19">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ffd:OffsetTableNa" id="f-20">N/A</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-13</xbrli:startDate><xbrli:endDate>2026-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875320</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-13</xbrli:startDate><xbrli:endDate>2026-05-13</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-7 f-8 f-10 f-11 f-12 f-13 f-14" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/></ix:resources></ix:header></div><div id="if23831f79c2648d983889312f23dda47_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 107</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">Calculation of Filing Fee Tables</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">Form <ix:nonNumeric contextRef="c-1" name="ffd:SubmissnTp" id="f-1"><ix:nonNumeric contextRef="c-1" name="ffd:FormTp" id="f-2">S-8</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Form Type)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">Vertex Pharmaceuticals Incorporated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Table 1: Newly Registered Securities</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Security Type</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Security Class Title</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fee Calculation Rule</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount Registered</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Proposed Maximum Offering Price Per Share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Maximum  Aggregate Offering Price</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fee Rate</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount of Registration Fee</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="ffd:OfferingSctyTp" id="f-3">Equity</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="ffd:OfferingSctyTitl" id="f-4">Common stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="ffd:FeesOthrRuleFlg" format="ixt:fixed-true" id="f-5">457(c) and 457(h)</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="ffd:AmtSctiesRegd" format="ixt:num-dot-decimal" id="f-6">6,400,000</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" name="ffd:MaxOfferingPricPerScty" scale="0" id="f-7">426.53</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="ffd:MaxAggtOfferingPric" format="ixt:num-dot-decimal" scale="0" id="f-8">2,729,792,000</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="number" contextRef="c-2" decimals="7" name="ffd:FeeRate" scale="0" id="f-9">0.0001381</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="2" name="ffd:FeeAmt" format="ixt:num-dot-decimal" scale="0" id="f-10">376,984.28</ix:nonFraction></span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total Offering Amounts</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ffd:TtlOfferingAmt" format="ixt:num-dot-decimal" scale="0" id="f-11">2,729,792,000</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="2" name="ffd:TtlFeeAmt" format="ixt:num-dot-decimal" scale="0" id="f-12">376,984.28</ix:nonFraction></span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total Fee Offsets</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="2" name="ffd:TtlOffsetAmt" scale="0" id="f-13">0.00</ix:nonFraction></span></td></tr><tr><td colspan="15" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net Fee Due</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"><div style="text-indent:36pt"><span><br/></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="2" name="ffd:NetFeeAmt" format="ixt:num-dot-decimal" scale="0" id="f-14">376,984.28</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Consists of 6,400,000 shares of common stock, par value $0.01 per share, that may be issued under the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the &#8220;2026 Plan&#8221;) that became effective May 13, 2026 (the &#8220;Effective Date&#8221;). The maximum number of shares that may be issued under the 2026 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2026 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares that may be subject to grant or otherwise issuable after the operation of any such anti-dilution provisions, stock splits, or other similar transactions.</span></ix:footnote></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><ix:nonNumeric contextRef="c-2" name="ffd:OfferingNote" id="f-15" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant&#8217;s common stock on the Nasdaq Global Select Market on May 8, 2026.</span></div></ix:nonNumeric></ix:footnote></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>a2026s-8_ex51xopinion2026p.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ie6a61809f0df46da8e117323affc7f11_1"></div><div style="min-height:90pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 5.1</font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:62px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.854%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;letter-spacing:0.007em;line-height:11.00pt">ROPES &#38; GRAY LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;letter-spacing:0.007em;line-height:11.00pt">PRUDENTIAL TOWER</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;letter-spacing:0.007em;line-height:11.00pt">800 BOYLSTON STREET</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;letter-spacing:0.007em;line-height:11.00pt">BOSTON, MA 02199-3600</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;letter-spacing:0.007em;line-height:11.00pt">WWW.ROPESGRAY.COM</font></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:60pt;margin-top:54pt;padding-left:108pt;padding-right:108pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">May 13, 2026</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Vertex Pharmaceuticals Incorporated</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">50 Northern Avenue</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Boston, MA 02210</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), filed by Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), for the registration of 6,400,000 shares of common stock, $0.01 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Shares are issuable pursuant to the Company&#8217;s 2026 Stock and Option Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We are familiar with the actions taken by the Company in connection with the adoption of the Plan.  We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein.  In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The opinions expressed below are limited to the Massachusetts Business Corporation Act. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plan, the Shares will be validly issued, fully paid and nonassessable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement.  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"><br>&#47;s&#47; Ropes &#38; Gray LLP</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"><br>Ropes &#38; Gray LLP</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>a2026s-8_ex231xeyconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i25bad6a2535041c680c4e3bbbd90357d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:173%">Exhibit 23.1</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:173%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:173%">We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2026 Stock and Option Plan of Vertex Pharmaceuticals Incorporated of our reports dated February 13, 2026, with respect to the consolidated financial statements of Vertex Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Vertex Pharmaceuticals Incorporated included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:14pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.497%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:173%">Boston, Massachusetts</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:173%">May 13, 2026</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a2026s-8_ex9912026stockand.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic6acb99dde774bfa8ff69058f994bc8a_37"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">VERTEX PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">2026 STOCK AND OPTION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">DEFINED TERMS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and includes certain operational rules related to those terms.  </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">PURPOSE</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock and Stock-based Awards.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">ADMINISTRATION</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Plan will be administered by the Administrator.  The Administrator has discretionary authority, subject only to the express provisions of the Plan, to administer and interpret the Plan and any Awards&#59; to determine eligibility for and grant Awards&#59; to determine the exercise price, base value from which appreciation is measured, or purchase price, if any, applicable to any Award, to determine, modify, accelerate or waive the terms and conditions of any Award&#59; to determine the form of settlement of Awards (whether in cash, shares of Stock, other Awards or other property)&#59; to prescribe forms, rules and procedures relating to the Plan and Awards&#59; and to otherwise do all things necessary or desirable to carry out the purposes of the Plan or any Award.  Determinations of the Administrator made with respect to the Plan or any Award are conclusive and bind all persons.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">SHARE POOL&#59; LIMITS ON AWARDS UNDER THE PLAN</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  Subject to adjustment as provided in Section 7(b) below, the maximum number of shares of Stock that may be delivered in satisfaction of Awards under the Plan is 6,400,000 shares, plus (i) the number of shares of Stock that as of the Effective Date are subject to awards under the Company&#8217;s Amended and Restated 2013 Stock and Option Plan (the &#8220;2013 Plan&#8221;) and that on or after the Effective Date expire or are terminated, surrendered or canceled without the delivery of any shares of Stock, or are forfeited or reacquired by the Company, in accordance with the terms of such plan, including the fungible share ratio set forth therein, and (ii) the number of shares of Stock that as of the Effective Date remain available for issuance under the 2013 Plan (which, in the case of (i) and (ii), shall not exceed 13,232,240 shares, prior to the application of the fungible share ratio set forth in the 2013 Plan) (such aggregate number of shares of Stock, the &#8220;Share Pool&#8221;).  Up to the total number of shares of Stock from the Share Pool may be delivered in satisfaction of ISOs, but nothing in this Section 4(a) will be construed as requiring that any, or any fixed number of, ISOs be granted under the Plan.  For purposes of determining the share limits under this Section 4(a), (i) each share of Stock subject to a Stock Option or SAR will count as one share and each share of Stock subject to any other Award will count as 1.66 shares, and (ii) the number of shares of Stock delivered in satisfaction of Awards will be determined (A) by reducing the Share Pool by the number of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">shares of Stock withheld by the Company in payment of the exercise price or purchase price of an Award or an award granted under the 2013 Plan or in satisfaction of tax withholding requirements with respect to an Award or an award granted under the 2013 Plan, (B) by reducing the Share Pool by the full number of shares covered by a SAR any portion of which is settled in Stock (and not only the number of shares of Stock delivered in settlement), and (C) by increasing the Share Pool by any shares of Stock underlying any portion of an Award or an award granted under the 2013 Plan that is settled in cash or that expires, becomes unexercisable, terminates or is forfeited to or repurchased by the Company without the issuance (or retention, in the case of Restricted Stock or Unrestricted Stock) of Stock. For the avoidance of doubt, the Share Pool will not be increased by any shares of Stock delivered under the Plan that are subsequently repurchased using proceeds directly attributable to Stock Option exercises.  The limits set forth in this Section 4(a) will be construed to comply with the applicable requirements of Section 422.  </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Substitute Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> The Administrator may grant Substitute Awards under the Plan.  To the extent consistent with the requirements of Section 422 and the regulations thereunder and other applicable legal requirements (including applicable stock exchange requirements), shares of Stock delivered in respect of Substitute Awards will be in addition to and will not reduce the Share Pool.  Notwithstanding the foregoing or anything in Section 4(a) to the contrary, if any Substitute Award is settled in cash or expires, becomes unexercisable, terminates or is forfeited to or repurchased by the Company without the delivery (or retention, in the case of Restricted Stock or Unrestricted Stock) of Stock, the shares of Stock previously subject to such Award will not increase the Share Pool or otherwise be available for future grant under the Plan.  The Administrator will determine the extent to which the terms and conditions of the Plan apply to Substitute Awards, if at all&#59; provided, however, that Substitute Awards will not be subject to the limits described in Section 4(d) below.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Type of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  Stock delivered by the Company under the Plan may be authorized but unissued Stock, treasury Stock or previously issued Stock acquired by the Company.  Fractional shares of Stock may be delivered under the Plan subject to such rules and procedures as determined by the Administrator from time to time.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Director Limits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary under the Plan, the aggregate value of all compensation granted or paid to any Director with respect to any calendar year, including Awards granted under the Plan and cash fees or other compensation paid by the Company to such Director outside of the Plan for his or her services as a Director during such calendar year, may not exceed $1,250,000 in the aggregate, calculating the value of any Awards based on the grant date fair value in accordance with the Accounting Rules and assuming a maximum payout, to the extent applicable.  For the avoidance of doubt, the limitation in this Section 4(d) will not apply to any compensation granted or paid to a Director for his or her services to the Company or an affiliate other than as a Director, including, without limitation, as a consultant, advisor or other service provider to the Company or an affiliate. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">ELIGIBILITY AND PARTICIPATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Administrator will select Participants from among Employees and Directors of, and consultants and advisors to, the Company and its affiliates&#59; provided, however, that, subject to such express exceptions, if any, as the Administrator may establish, eligibility shall be further </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">limited to those persons as to whom the use of a Form S-8 registration statement is permissible.  Eligibility for ISOs is limited to individuals who are employees of the Company or of a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; of the Company as those terms are defined in Section 424 of the Code.  Eligibility for Stock Options, other than ISOs, and SARs is limited to individuals described in the first sentence of this Section 5 who are providing direct services on the date of grant of the Award to the Company or to a subsidiary of the Company that would be described in the first sentence of Section 1.409A-1(b)(5)(iii)(E) of the Treasury Regulations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">RULES APPLICABLE TO AWARDS</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">All Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Award Provisions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Administrator will determine the terms and conditions of all Awards, subject to the limitations provided herein.  No term of an Award shall provide for automatic &#8220;reload&#8221; grants of additional Awards upon the exercise of an Option or SAR.  By accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an Award, the Participant agrees (or will be deemed to have agreed) to the terms and conditions of the Award and the Plan.  Notwithstanding any provision of the Plan to the contrary, Substitute Awards may contain terms and conditions that are inconsistent with the terms and conditions specified herein, as determined by the Administrator.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  No Awards may be made after May 13, 2036 but previously granted Awards may continue beyond that date in accordance with their terms. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Neither ISOs nor, except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section 6(a)(3), other Awards may be transferred other than by will, by the laws of descent and distribution or pursuant to a validly issued domestic relations order.  During a Participant&#8217;s lifetime, ISOs and, except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section 6(a)(3), SARs and NSOs may be exercised only by the Participant.  The Administrator may permit the gratuitous transfer (i.e., transfer not for value) of Awards other than ISOs, including for estate planning purposes, subject to applicable securities and other laws and such terms and conditions as the Administrator may determine&#59; for avoidance of doubt, no Award may be transferred for consideration to a third party.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Vesting&#59; Exercisability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> The Administrator will determine the time or times at which an Award vests or becomes exercisable and the terms and conditions on which a Stock Option or SAR remains exercisable.  Without limiting the foregoing, the Administrator may at any time accelerate the vesting and&#47;or exercisability of an Award (or any portion thereof), regardless of any adverse or potentially adverse tax or other consequences resulting from such acceleration, including in connection with a Covered Transaction or other transaction or event.  Unless the Administrator expressly provides otherwise, however, the following rules will apply if a Participant&#8217;s Employment ceases&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Immediately upon the cessation of the Participant&#8217;s Employment, each unvested Stock Option and SAR (or portion thereof) that is then held by the Participant or by the Participant&#8217;s permitted transferees, if any, will cease to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">exercisable and will terminate and each other unvested Award (or portion thereof) that is then held by the Participant or by the Participant&#8217;s permitted transferees, if any, will be forfeited.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to (C) and (D) below, each Stock Option and SAR (or portion thereof) held by the Participant or the Participant&#8217;s permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Employment, to the extent then vested and exercisable, will remain exercisable for the lesser of (i) a period of ninety (90) days following such cessation of Employment or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon immediately terminate.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to (D) below, each Stock Option and SAR (or portion thereof) held by a Participant or the Participant&#8217;s permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Employment due to the Participant&#8217;s death or by the Company due to the Participant&#8217;s Disability, to the extent then vested and exercisable, will remain exercisable for the lesser of (i) the one-year period ending on the first anniversary of such cessation of Employment or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon immediately terminate.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All Awards (whether or not vested or exercisable) held by a Participant or the Participant&#8217;s permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Employment will immediately terminate upon (i) such cessation of Employment if the termination is for Cause or occurs in circumstances that in the determination of the Administrator would have constituted grounds for the Participant&#8217;s Employment to be terminated for Cause (in each case, without regard to the lapsing of any required notice or cure periods in connection therewith) or (ii) to the maximum extent permitted under applicable law, the Participant&#8217;s violation of any non-competition, non-solicitation, no-hire, non-disparagement, confidentiality, invention assignment, or other restrictive covenant in favor of the Company or any of its affiliates by which the Participant is bound.   </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Recovery of Compensation&#59; Other Policies.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  The Administrator may provide in any case that any outstanding Award (whether or not vested or exercisable), the proceeds from the exercise or disposition of any Award or Stock acquired under any Award, and any other amounts received in respect of any Award or Stock acquired under any Award will be subject to forfeiture and disgorgement to the Company, with interest and other related earnings, if the Participant to whom the Award was granted is not in compliance with any provision of the Plan or any applicable Award or violates any non-competition, non-solicitation, no-hire, non-disparagement, confidentiality, invention assignment or other restrictive covenant by which the Participant is bound.  Each Award will be subject to any policy of the Company or any of its affiliates that relates to trading on non-public information and permitted transactions with respect to shares of Stock, including limitations on hedging and pledging.  In addition, each Award will be subject to recoupment to the extent a Participant is or becomes subject to the Company&#8217;s Policy for Recoupment of Incentive Compensation, effective October 2, 2023, the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">March 2013 Recoupment Policy, or any other policy of the Company or any of its affiliates that provides for forfeiture, disgorgement, or clawback with respect to incentive compensation that includes Awards under the Plan (the &#8220;Clawback Policies&#8221;).  Each Participant, by accepting or being deemed to have accepted an Award under the Plan, agrees (or will be deemed to have agreed) to the terms of this Section 6(a)(5), and to the Clawback Policies, if applicable, and further agrees (or will be deemed to have further agreed) to cooperate fully with the Administrator, and to cause any and all permitted transferees of the Participant to cooperate fully with the Administrator, to effectuate any forfeiture, recoupment or disgorgement described in this Section 6(a)(5).  Neither the Administrator nor the Company nor any other person, other than the Participant and the Participant&#8217;s permitted transferees, if any, will be responsible for any adverse tax or other consequences to a Participant or the Participant&#8217;s permitted transferees, if any, that may arise in connection with this Section 6(a)(5).</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The grant of an Award and the issuance, delivery, vesting and retention of Stock, cash or other property under an Award are conditioned upon the full satisfaction by the Participant of all tax and other withholding requirements with respect to the Award under applicable laws.  The Administrator will prescribe such rules for the withholding of taxes and other amounts with respect to any Award as it deems necessary.  Without limiting the foregoing, the Company or any affiliate of the Company will have the authority and the right to deduct or withhold (by any means set forth herein or in an Award agreement), or require a Participant to remit to the Company or an affiliate of the Company, an amount sufficient to satisfy all U.S. and non-U.S. federal, state and local income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to participation in the Plan and any Award hereunder and legally applicable to the Participant and required by law to be withheld (including, any amount deemed by the Company, in its discretion, to be an appropriate charge to the Participant even if legally applicable to the Company or any affiliate of the Company).  Subject to applicable laws, the Administrator, in its sole discretion, may hold back shares of Stock from an Award or permit a Participant to tender previously-owned shares of Stock in satisfaction of tax or other withholding requirements (but not in excess of the maximum withholding amount consistent with the Award being subject to equity accounting treatment under the Accounting Rules).  Any amounts withheld pursuant to this Section 6(a)(6) will be treated as though such amounts had been paid directly to the applicable Participant.  In addition, the Company may, to the extent permitted by law, deduct any such tax and other withholding amounts from any payment of any kind otherwise due to a Participant from the Company or any of its affiliates. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  The Administrator may provide for the payment of amounts (on terms and subject to such restrictions and conditions established by the Administrator, including providing for the reinvestment of such amounts in the form of additional Awards) in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award, whether or not the holder of such Award is otherwise entitled to share in the actual dividend or distribution in respect of such Award&#59; provided, however, that (a) dividends or dividend equivalents relating to an Award that, at the dividend payment date, remain subject to a risk of forfeiture (whether service-based or performance-based) shall be subject to the same risk of forfeiture that applies to the underlying Award and (b) no dividends or dividend equivalents </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">shall be payable with respect to Stock Options or SARs.  Any entitlement to dividend equivalents or similar entitlements will be established and administered either consistent with an exemption from, or in compliance with, the applicable requirements of Section 409A. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Rights Limited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Nothing in the Plan or any Award will be construed as giving any person the right to be granted an Award or to continued employment or service with the Company or any of its affiliates, or any rights as a shareholder except as to shares of Stock actually delivered under the Plan.  The loss of existing or potential profit in any Award will not constitute an element of damages in the event of a termination of a Participant&#8217;s Employment for any reason, even if the termination is in violation of an obligation of the Company or any of its affiliates to the Participant.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Coordination with Other Plans</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  Shares of Stock and&#47;or Awards under the Plan may be issued or granted in tandem with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or any of its affiliates.  For example, but without limiting the generality of the foregoing, awards under other compensatory plans or programs of the Company or any of its affiliates may be settled in Stock (including, without limitation, Unrestricted Stock) under the Plan if the Administrator so determines, in which case the shares delivered will be treated as awarded under the Plan (and will reduce the Share Pool). </font></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;Reserved.</font></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Without limiting the generality of Section 11(a) below, each Award will contain such terms as the Administrator determines and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section 409A or satisfies such requirements.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in the Plan or any Award agreement, the Administrator may unilaterally amend, modify or terminate the Plan or any outstanding Award, including but not limited to changing the form of the Award, if the Administrator determines that such amendment, modification or termination is necessary or desirable to avoid the imposition of any additional tax, interest or penalty under Section 409A.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If a Participant is determined on the date of the Participant&#8217;s termination of Employment to be a &#8220;specified employee&#8221; within the meaning of that term under Section 409A(a)(2)(B) of the Code, then, with regard to any payment that is considered nonqualified deferred compensation under Section 409A, to the extent applicable, payable on account of a &#8220;separation from service&#8221;, such payment will be made or provided on the date that is the earlier of (i) the first business day following the expiration of the six-month period measured from the date of such &#8220;separation from service&#8221; and (ii) the date of the Participant&#8217;s death (the &#8220;Delay Period&#8221;).  Upon the expiration of the Delay Period, all payments delayed pursuant to this Section 6(a)(11)(C) (whether they would have otherwise been payable in a single lump sum or in installments </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">in the absence of such delay) will be paid, without interest, on the first business day following the expiration of the Delay Period in a lump sum and any remaining payments due under the Award will be paid in accordance with the normal payment dates specified for them in the applicable Award agreement.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For purposes of Section 409A, each payment made under the Plan or any Award will be treated as a separate payment.  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With regard to any payment considered to be nonqualified deferred compensation under Section 409A, to the extent applicable, that is payable upon a change in control of the Company or other similar event, to the extent required to avoid the imposition of any additional tax, interest or penalty under Section 409A, no amount will be payable unless such change in control constitutes a &#8220;change in control event&#8221; within the meaning of Section 1.409A-3(i)(5) of the Treasury Regulations.</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Stock Options and SARs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Time and Manner of Exercise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Unless the Administrator expressly provides otherwise, no Stock Option or SAR will be deemed to have been exercised until the Administrator receives a notice of exercise in a form acceptable to the Administrator that is signed by the appropriate person and accompanied by any payment required under the Award.  The Administrator may limit or restrict the exercisability of any Stock Option or SAR in its discretion, including in connection with any Covered Transaction.  Any attempt to exercise a Stock Option or SAR by any person other than the Participant will not be given effect unless the Administrator has received such evidence as it may require that the person exercising the Award has the right to do so.  If on the date the term of an NSO expires or on the last date such NSO is exercisable in accordance with Section 6(a)(4), the fair market value of a share of Stock exceeds the exercise price per share of the NSO, then the NSO shall automatically be exercised with respect to all then vested Shares underlying such NSO and, upon such automatic exercise, such NSO shall immediately terminate. In such case, payment of the exercise price for the shares of Stock as to which such NSO is being exercised, and all tax withholding requirements, shall be satisfied by the withholding of unrestricted shares of Stock otherwise deliverable upon such exercise as set forth in Section 6(b)(3) below.  As a result of such net exercise, the Participant shall receive (i) the number of shares of Stock underlying the portion of the NSO so being exercised, less (ii) such whole number of shares of Stock (rounded up to the nearest share) that is equal to (A) the aggregate exercise price for the portion of the NSO that is so being exercised plus the amount of all applicable tax withholdings associated with such exercise divided by (B) the fair market value of a share of Stock on the date of exercise.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> The exercise price (or the base value from which appreciation is to be measured) per share of each Award requiring exercise must be no less than 100% (in the case of an ISO granted to a 10-percent shareholder within the meaning of Section 422(b)(6) of the Code, 110%) of the Fair Market Value of a share of Stock, determined as of the date of grant of the Award, or such higher amount as the Administrator may determine in connection with the grant.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Payment of Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Where the exercise of an Award (or portion thereof) is to be accompanied by payment, payment of the exercise price must be made by cash or check acceptable to the Administrator or, if so permitted by the Administrator and if legally permissible, (i) through the delivery of previously acquired unrestricted shares of Stock, or the withholding of unrestricted shares of Stock otherwise deliverable upon exercise, in either case, that have a fair market value equal to the exercise price&#59; (ii) through a broker-assisted cashless exercise program acceptable to the Administrator&#59; (iii) by other means acceptable to the Administrator&#59; or (iv) by any combination of the foregoing permissible forms of payment.  The delivery of previously acquired shares in payment of the exercise price under clause (i) above may be accomplished either by actual delivery or by constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Maximum Term</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The maximum term of Stock Options and SARs must not exceed 10 years from the date of grant (or five years from the date of grant in the case of an ISO granted to a 10-percent shareholder described in Section 6(b)(2) above).</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">No Repricing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Except in connection with a corporate transaction involving the Company (which term includes, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination or exchange of shares) or as otherwise contemplated by Section 7 below, the Company may not, without obtaining shareholder approval, (i) amend the terms of outstanding Stock Options or SARs to reduce the exercise price or base value of such Stock Options or SARs, (ii) cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs that have an exercise price or base value that is less than the exercise price or base value of the original Stock Options or SARs, or (iii) cancel outstanding Stock Options or SARs that have an exercise price or base value greater than the fair market value of a share of Stock on the date of such cancellation in exchange for cash or other consideration.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">EFFECT OF CERTAIN TRANSACTIONS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Covered Transactions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Except as otherwise expressly provided in an Award agreement or other agreement or by the Administrator, the following provisions will apply in the event of a Covered Transaction&#58;</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Assumption or Substitution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Covered Transaction is one in which there is an acquiring or surviving entity, the Administrator may provide for (i) the assumption or continuation of some or all outstanding Awards or any portion thereof or (ii) the grant of new awards in substitution therefor by the acquiror or survivor or an affiliate of the acquiror or survivor.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Cash-Out of Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to Section 7(a)(5) below, the Administrator may provide for payment (a &#8220;cash-out&#8221;), with respect to some or all Awards or any portion thereof (including only the vested portion thereof, with the unvested portion terminating as provided in Section 7(a)(4) below), equal in the case of each applicable Award or portion thereof to the excess, if any, of (i) the fair market value of one share of Stock multiplied by the number of shares of Stock subject to the Award or such portion, minus (ii) the aggregate exercise or purchase price, if any, of such Award or such portion thereof (or, in the case of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">SAR, the aggregate base value above which appreciation is measured), in each case, on such payment and other terms and subject to such conditions (which need not be the same as the terms and conditions applicable to holders of Stock generally) as the Administrator determines,  including that any amounts paid in respect of such Award in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate.  For the avoidance of doubt, if the per share exercise or purchase price (or base value) of an Award or portion thereof is equal to or greater than the fair market value of one share of Stock, as determined in connection with the Covered Transaction, such Award or portion may be cancelled with no payment due hereunder or otherwise in respect thereof.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Acceleration of Certain Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  Subject to Section 7(a)(5) below, the Administrator may provide that any Award requiring exercise will become exercisable, in full or in part, and&#47;or that the delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including Restricted Stock Units and Performance Awards to the extent consisting of Stock Units) will be accelerated, in full or in part, in each case on a basis that gives the holder of the Award a reasonable opportunity, as determined by the Administrator, following the exercise of the Award or the delivery of the shares, as the case may be, to participate as a shareholder in the Covered Transaction. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Termination of Awards upon Consummation of Covered Transaction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Except as the Administrator may otherwise determine, each Award will automatically terminate (and in the case of outstanding shares of Restricted Stock, will automatically be forfeited) immediately upon the consummation of the Covered Transaction&#59; provided, however, that unless the Administrator provides for the assumption, continuation or substitution of Awards pursuant to Section 7(a)(1) above, all outstanding Awards shall become immediately and fully exercisable, any applicable vesting conditions shall be deemed satisfied, with any performance vesting conditions deemed to be satisfied in full, and any forfeiture restrictions shall be deemed to have lapsed, in each case as of immediately prior to the consummation of the Covered Transaction.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Limitations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any share of Stock and any cash or other property or other award delivered pursuant to Section 7(a)(1), Section 7(a)(2) or Section 7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions, if any, as the Administrator deems appropriate, including to reflect any performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction.  For purposes of the immediately preceding sentence, a cash-out under Section 7(a)(2) above or an acceleration under Section 7(a)(3) above will not, in and of itself, be treated as the lapsing (or satisfaction) of a performance or other vesting condition.  In the case of Restricted Stock that does not vest and is not forfeited in connection with the Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Uniform Treatment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> For the avoidance of doubt, the Administrator need not treat Participants or Awards (or portions thereof) in a uniform manner, and may treat different Participants and&#47;or Awards differently, in connection with a Covered Transaction.</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Changes in and Distributions with Respect to Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Basic Adjustment Provisions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  In the event of a stock dividend, extraordinary cash dividend, stock split or combination of shares (including a reverse stock split), recapitalization, reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off, split-up or other similar change in the Company&#8217;s capital structure that constitutes an equity restructuring within the meaning of the Accounting Rules, the Administrator shall make appropriate adjustments to the Share Pool, and shall make appropriate adjustments to the number and kind of shares of stock or securities underlying Awards then outstanding or subsequently granted, any exercise or purchase prices (or base values) relating to Awards and any other provision of Awards affected by such change. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;Certain Other Adjustments. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> The Administrator may also make adjustments of the type described in Section 7(b)(1) above to take into account distributions to shareholders other than those provided for in Sections 7(a) and 7(b)(1) above, or any other event, if the Administrator determines that adjustments are appropriate to avoid distortion in the operation of the Plan or any Award, having due regard for the qualification of ISOs under Section 422 and the requirements of Section 409A, to the extent applicable. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;Continuing Application of Plan Terms. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> References in the Plan to shares of Stock will be construed to include any stock or securities resulting from an adjustment pursuant to this Section 7.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">LEGAL CONDITIONS ON DELIVERY OF STOCK</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until&#58; (i) the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved&#59; (ii) if the outstanding Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance&#59; and (iii) all conditions of the Award have been satisfied or waived.  The Company may require, as a condition to the exercise of an Award or the delivery of shares of Stock under an Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of the Securities Act of 1933, as amended, or any applicable state or non-U.S. securities law.  Any Stock delivered to Participants under the Plan will be evidenced in such manner as the Administrator determines appropriate, including book-entry registration or delivery of stock certificates.  In the event that the Administrator determines that stock certificates will be issued in connection with Stock issued under the Plan, the Administrator may require that such certificates bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold the certificates pending the lapse of the applicable restrictions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;AMENDMENT AND TERMINATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by applicable law, and may at any time terminate the Plan as to any future grants of Awards&#59; provided, however, that except as otherwise expressly provided in the Plan or the applicable Award, the Administrator may not, without the Participant&#8217;s consent, alter the terms of an Award so as to affect materially and adversely the Participant&#8217;s rights under the Award, unless the Administrator expressly reserved the right to do so in the Plan or at the time the applicable Award was granted.   Any amendments to the Plan will be conditioned upon shareholder approval only to the extent, if any, such approval is required by applicable law (including the Code) or stock exchange requirements, as determined by the Administrator.  For the avoidance of doubt, without limiting the Administrator&#8217;s rights hereunder, no adjustment to any Award pursuant to the terms of Section 7 or Section 12 will be treated as an amendment requiring a Participant&#8217;s consent.   </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;OTHER COMPENSATION ARRANGEMENTS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The existence of the Plan or the grant of any Award will not affect the right of the Company or any of its affiliates to grant any person bonuses or other compensation in addition to Awards under the Plan.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;MISCELLANEOUS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">By accepting or being deemed to have accepted an Award under the Plan, each Participant waives (or will be deemed to have waived), to the maximum extent permitted under applicable law, any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan or any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees (or will be deemed to have agreed) that any such action, proceedings or counterclaim will be tried before a court and not before a jury.  By accepting (or being deemed to have accepted) an Award under the Plan, each Participant certifies that no officer, representative, or attorney of the Company or any of its affiliates has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers.  Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit any disputes arising under the terms of the Plan or any Award made hereunder to binding arbitration or as limiting the ability of the Company to require any individual to agree to submit such disputes to binding arbitration as a condition of receiving an Award hereunder. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in the Plan or any Award, none of the Company, nor any of its affiliates, nor the Administrator, nor any person acting on behalf of the Company, any of its affiliates, or the Administrator, will be liable to any Participant, to any permitted transferee, to the estate or beneficiary of any Participant or any permitted transferee, or to any other person by reason of any acceleration of income, any additional tax, or any penalty, interest or other liability asserted by reason of the failure of an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Award to satisfy the requirements of Section 422 or Section 409A or by reason of Section 4999 of the Code, or otherwise asserted with respect to any Award. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Unfunded Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  The Company&#8217;s obligations under the Plan are unfunded, and no Participant will have any right to specific assets of the Company in respect of any Award.  Participants will be general unsecured creditors of the Company with respect to any amounts due or payable under the Plan.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;ESTABLISHMENT OF SUB-PLANS</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Administrator may at any time and from time to time (including before or after an Award is granted) establish, adopt, or revise any rules and regulations as it may deem necessary or advisable to administer the Plan for Participants based outside of the U.S. and&#47;or subject to the laws of countries other than the U.S., including by establishing one or more sub-plans, supplements or appendices under the Plan or any Award agreement for the purpose of complying or facilitating compliance with non-U.S. laws or taking advantage of tax favorable treatment or for any other legal or administrative reason determined by the Administrator.  Any such sub-plan, supplement or appendix may contain, in each case, (i) such limitations on the Administrator&#8217;s discretion under the Plan and (ii) such additional or different terms and conditions, as the Administrator deems necessary or desirable and will be deemed to be part of the Plan but will apply only to Participants within the group to which the sub-plan, supplement or appendix applies (as determined by the Administrator)&#59; provided, however, that no sub-plan, supplement or appendix, rule or regulation established pursuant to this provision shall increase the Share Pool.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;GOVERNING LAW</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Certain Requirements of Corporate Law.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Awards and shares of Stock will be granted, issued and administered consistent with the requirements of applicable Massachusetts law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is listed or entered for trading, in each case as determined by the Administrator.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Other Matters.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise provided by the express terms of an Award agreement or under a sub-plan described in Section 12 above, the domestic substantive laws of the Commonwealth of Massachusetts govern the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of or based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Jurisdiction. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to Section 11(a) and except as may be expressly set forth in an Award agreement, by accepting (or being deemed to have accepted) an Award, each Participant agrees or will be deemed to have agreed to (i) submit irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon the Plan or any Award&#59; (ii) not commence any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">suit, action or other proceeding arising out of or based upon the Plan or any Award, except in the federal and state courts located within the geographic boundaries of the United States District Court for the District of Massachusetts&#59; and (iii) waive, and not assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim that the Participant is not subject personally to the jurisdiction of the above-named courts, that the Participant&#8217;s property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that the Plan or any Award or the subject matter thereof may not be enforced in or by such court.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;The remainder of this page is intentionally left blank.&#93;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Definition of Terms</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The following terms, when used in the Plan, have the meanings and are subject to the provisions set forth below&#58;</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Accounting Rules&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor provision.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Administrator&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> The Compensation Committee, except that the Board may at any time act in the capacity of the Administrator (including with respect to such matters that are not delegated to the Compensation Committee by the Board (whether pursuant to committee charter or otherwise), if applicable).  The Compensation Committee (or the Board, with respect to such matters over which it retains authority under the Plan or otherwise) may delegate (i) to one or more of its members (or one or more other members of the Board) such of its duties, powers and responsibilities as it may determine&#59; (ii) to one or more officers of the Company the power to grant Awards to the extent permitted by applicable law&#59; and (iii) to such Employees or other persons as it determines such ministerial tasks as it deems appropriate.  For purposes of the Plan, the term &#8220;Administrator&#8221; will include the Board, the Compensation Committee, and the person or persons delegated authority under the Plan to the extent of such delegation, as applicable.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Award&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Any or a combination of the following&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i) Stock Options. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii) SARs.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iii) Restricted Stock.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iv) Unrestricted Stock.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(v) Stock Units, including Restricted Stock Units.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(vi) Performance Awards.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(vii) Awards (other than Awards described in (i) through (vi) above) that are convertible into or otherwise based on Stock. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Board&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The board of directors of the Company.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Cause&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) the Participant&#8217;s dishonesty in the performance of his or her duties to the Company or its affiliates or fraud, or (ii) the willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company or its affiliates (including, without limitation, any material breach by the Participant of any provision of any Company policy or any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company or any of its affiliates), in each case as determined in good faith by the Company, which determination shall be conclusive&#59; provided, however, that if there is a conflict between this definition of Cause and either (1) the definition of &#8220;Cause&#8221; contained in any employment or other individual service agreement between the Company and the Participant or (2) the definition of &#8220;Cause&#8221; contained </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">in any change of control agreement between the Company and the Participant, then such other definition shall be controlling for the purposes of the Plan.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Change of Control&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">shall mean that (a) any &#8220;person&#8221; or &#8220;group&#8221; as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;Act&#8221;), becomes a beneficial owner, as such term is used in Rule 13d-3 promulgated under the Act, of securities of the Company representing more than 50% of the combined voting power of the outstanding securities of the Company having the right to vote in the election of directors&#59; or (b) all or substantially all the business or assets of the Company are sold or disposed of, or the Company or a subsidiary of the Company combines with another company pursuant to a merger, consolidation, or other similar transaction, other than (i) a transaction solely for the purpose of reincorporating the Company or one of its subsidiaries in a different jurisdiction or recapitalizing or reclassifying the Company&#8217;s stock&#59; or (ii) a merger or consolidation in which the shareholders of the Company immediately prior to such merger or consolidation continue to own at least a majority of the outstanding voting securities of the Company or the surviving entity immediately after such merger or consolidation. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Code&#8221;&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  The U.S. Internal Revenue Code of 1986, as from time to time amended and in effect, or any successor statute as from time to time in effect, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Compensation Committee&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Management Development and Compensation Committee of the Board. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Company&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Vertex Pharmaceuticals Incorporated, a Massachusetts corporation.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Covered Transaction&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any of (i) a consolidation, merger or similar transaction or series of related transactions, including a sale or other disposition of stock, in which the Company is not the surviving entity or which results in the acquisition of all or substantially all of the Company&#8217;s then outstanding common stock by a single person or entity or by a group of persons and&#47;or entities acting in concert, (ii) a sale or transfer of all or substantially all the Company&#8217;s assets, (iii) a dissolution or liquidation of the Company or (iv) a Change of Control. Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed to have occurred upon consummation of the tender offer.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Director&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A member of the Board who is not an Employee.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Disability&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A disability entitling a Participant to benefits under the Company&#8217;s long-term disability program, as in effect from time to time. With regard to any payment considered to be nonqualified deferred compensation under Section 409A, to the extent applicable, that is payable upon a cessation of a Participant&#8217;s Employment due to Disability, to avoid the imposition of an additional tax, interest or penalty under Section 409A, no amount will be payable unless such Disability constitutes a disability or becoming disabled within the meaning of Section 1.409A-3(i)(4) of the Treasury Regulations.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Effective Date&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The date the Plan is approved by shareholders of the Company.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Employee&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any person who is employed by the Company or any of its affiliates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Employment&#8221;&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  A Participant&#8217;s employment or other service relationship with the Company or any of its affiliates.  Employment will be deemed to continue, unless the Administrator otherwise determines, so long as the Participant is employed by, or otherwise is providing services in a capacity described in Section 5 of the Plan to, the Company or any of its affiliates.  If a Participant&#8217;s employment or other service relationship is with any affiliate of the Company and that entity ceases to be an affiliate of the Company, the Participant&#8217;s Employment will be deemed to have terminated when the entity ceases to be an affiliate of the Company unless the Participant transfers Employment to the Company or one of its remaining affiliates.  For purposes of the Plan, an approved leave of absence due to a temporary disability or that constitutes a standard paid leave under Company policies as in effect from time to time shall not be deemed to be a termination of Employment, except as the Administrator may otherwise expressly provide or except as otherwise provided by law.  </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in construing the provisions of any Award relating to the payment of &#8220;nonqualified deferred compensation&#8221; (subject to Section 409A) upon a termination or cessation of Employment, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms will be construed to require a &#8220;separation from service&#8221; (as that term is defined in Section 1.409A-1(h) of the Treasury Regulations, after giving effect to the presumptions contained therein) from the Company and from all other corporations and trades or businesses, if any, that would be treated as a single &#8220;service recipient&#8221; with the Company under Section 1.409A-1(h)(3) of the Treasury Regulations.  The Company may, but need not, elect in writing, subject to the applicable limitations under Section 409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a &#8220;separation from service&#8221; has occurred.  Any such written election will be deemed a part of the Plan.  </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Fair Market Value&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">As of a particular date, (i) the mean between the highest and lowest quoted selling prices for a share of Stock reported on the Nasdaq Market System (or any other national securities exchange on which the Stock is then listed) for that date or, if there were no sales on such date, on the next preceding date within a reasonable period (as determined in the sole discretion of the Administrator) on which there were sales or (ii) in the event that the Stock is not traded on a national securities exchange, the fair market value of a share of Stock determined by the Administrator consistent with the rules of Section 422 and Section 409A to the extent applicable.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;ISO&#8221;&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  A Stock Option intended to be an &#8220;incentive stock option&#8221; within the meaning of Section 422.  Each Stock Option granted pursuant to the Plan will be treated as providing by its terms that it is to be an NSO unless, as of the date of grant, it is expressly designated as an ISO in the applicable Award agreement.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;NSO&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A Stock Option that is not intended to be an &#8220;incentive stock option&#8221; within the meaning of Section 422.  </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Participant&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A person who is granted an Award under the Plan.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Performance Award&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">An Award subject to performance vesting conditions, which may include Performance Criteria.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Performance Criteria&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Specified criteria, other than the mere continuation of Employment or the mere passage of time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award.  A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result or avoidance of loss and may be applied, without limitation, to a Participant individually, to a group of individual Participants, or to a business unit or division of the Company or to the Company as a whole.  A Performance Criterion may also be based on individual performance and&#47;or subjective performance criteria (or any combination of any of the criteria described in this definition).  The Administrator may provide that one or more of the Performance Criteria applicable to such Award will be adjusted in a manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria.    </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Plan&#8221;&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  The Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan, as from time to time amended and in effect.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Restricted Stock&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Stock subject to restrictions requiring that it be forfeited, redelivered or offered for sale to the Company if specified performance or other vesting conditions are not satisfied.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Restricted Stock Unit&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A Stock Unit that is, or as to which the delivery of Stock or of cash in lieu of Stock is, subject to the satisfaction of specified performance or other vesting conditions.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;SAR&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> A right entitling the holder upon exercise to receive an amount (payable in cash or in shares of Stock of equivalent value) equal to the excess of the Fair Market Value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be measured.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Section 409A&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Section 409A of the Code and the regulations thereunder.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Section 422&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Section 422 of the Code and the regulations thereunder.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Stock&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Common stock of the Company, par value $.01 per share.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Stock Option&#8221;&#58;  A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">n option entitling the holder to acquire shares of Stock upon payment of the exercise price.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Stock Unit&#8221;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">An unfunded and unsecured promise, denominated in shares of Stock, to deliver Stock or cash measured by the value of Stock in the future.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Substitute Award&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> An award granted under the Plan in substitution for one or more equity awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Unrestricted Stock&#8221;&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Stock not subject to any restrictions under the terms of the Award.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@   /    $Q" (   #-]+A@     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    @8TA230  >B8  ("$  #Z    @.@  '4P
M  #J8   .I@  !=PG+I1/     EP2%ES   N(P  +B,!>*4_=@    =T24U%
M!]@"%0X3 3/(G"$    8=$58=%-O9G1W87)E %%U:6-K5&EM92 W+C0N,5B&
MM\4  $AA241!5'A>[7UY5%5)FF?.Z3,S9V9Z:DYG;5E+5F5M64MF5V6?JJQ3
M55U=W5VY9YJF9J:[HH(@LH@(""(@.R**B@N+B"("@NP@(N""H*C@KH"BHH*
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M[&(]_[+E1M[O&UBT*A86 .:+((/_W<X[-N<@\_$'CQZ=O7K+9=V.MV:YRIW
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M?_4EN_D86JJF'SQN$*P\ P2@!:"?'Z#G!44SM0[T\7:*B$>K7Q[(*H\1@!:
M?GZ WEMY%HV0F9C^F]V*"E-<#06@!:"?'Z![^@?^9N?#!#0:6[E$)MRY>]](
M(2T +0#]_  ]].#AYJP2N3;F?[+VS#AT0@!ZS+9U&S.EP'0811OUYHZ[Z/''
M%-+?^W">_:H8## &TT)""PG]_"0TD HA'9%2  <A$]-_G.>16F(4/0+0 M!&
M 4BM-(60OGK[SI]M& WH 7'DL"P(V7+;""$M "T _5P!C0/0-S"4D'^(V7$8
MF'YKEFMJ<87:<Z(;_YP _>_V*S63B =%3J%%YQ326W^GJ_M]YT"Y-!:;H$U7
MF^YH XR) 3W';QU3/9KF&Z6-/NDI >@Q!NC!!P]3BX_B%L@.DI[F')==H@TP
M)@;T)/?0E]^915.)?$9M] E T\RTN"19YM;?:&[[Q#5$3DC/]8_2)J1-">CJ
MRPU_7<!6]B-2"P6@U7(@.#%W;#2O9RX<,= Y954_G;20N<9?37%**BQ3RS&,
M-R6@(Y(+7O_"@4G?Z?J;&HC3/3(^50[[B(0Q#&AL+DS.\P+9,:5POLP-V'CA
M6J-:V)@,T"U=W9.7A7^;Y:G_Z21[Z$QJ*=,?/SX!_8YCP-@&](.'CPJ.GOKY
M9'OF,O'WJ/1"M<@Q&: W["[X^>=LRN8'11N#YO%Y*41\\ \_L:%W&E>4SSW"
MU/+SQ=:V4Z"VH:7=-BR&">AOOC-KDD=X=5V#JL6: -"(^MM><.A/\Y<QP[=?
M_=BZNO:Z*IKHP>-00@=MSV9N\W<_F&L7JEI F"V@(8 +CYUY_0M'=C++9W;Q
MN:6JA+2Q@*XX?\5UW?;?SG"1<V8BIW? Z#C7\0;HE))*Z&ER>[PFN4"M@#!;
M0&,A;7>[O:-3F(L=_AQY19RX=)5_O6Q OSK!QF%- K@@]]M=>CQX>[9-\&:8
M-7[TZ0*FJ0XDS@O: N/+8[@[C?LWK@ =GW?X#U;NS W&'_]@Y59[LUDM.Q4
M[1>?J;#1<O_IVNTVM33(C4?EI/TGSOUVYE*Y QR;7<POI-F AO+PVD2[-V<L
MEOO]:HKCCR?:XO/W,JLKG.24MPZ.OM'2_I71:!X_.G3>T3,+0J)_^:6CG(!
MT#"XJJ%VE@*@?S;97F&CY?[3EHQ]I@(TYFGMNA>0L$=.2'_@$GRRYAKGZ]B
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M+'2??V/ZXK\M7/&I6XBT=].](SY:$OC'><M>_\*1>7W2;=_OK9;!V/KXB67
M,LQV.I:=JFOX<'&@\O+D1+C<WW_^N<.:Y/RV+HW6.AUM%BJAU;)+?_PO/G?(
M+^>]U4%(!R3L4?A(:J,$-NFDHO('#Y_Z(BP,T \?/3Y^J7ZF7]3W/F+T$M7
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MCBZC%^HNRXW/V;N//@/H8JS03'Z$#HUY 4ITNB9FP3*"UJS%L4#;*,"=-J-
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M_Z RY1>7$,0@L$Y7?/I0Q5$B\PKF<!X3!UM"([*;KN9/O!YZ8>G768;,)0E
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M30 :02/&?)ATSXI+(>>E$.VRF7U@30YHSOY4EJ%#@\JK-VZXCBQ2!I85E)"
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MU!+AA0 T6I#KKQ_&N^5!P=KFQU,"T,J 1AN*Y8$A-."0)66DFU"W9<GI&4Q
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M\^M&IF;E$/=.'6=S]A6IG7#L 9KI55D>%&ID>JP^8Z%7K%RUFFGHT%#WP_2
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//B:3     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>May 13, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0000875320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">VERTEX PHARMACEUTICALS INC / MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th" colspan="2">
<div>May 13, 2026 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common stock, $0.01 par value per share<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="nump">426.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 2,729,792,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 376,984.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant&#8217;s common stock on the Nasdaq Global Select Market on May 8, 2026.</span></div><span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Consists of 6,400,000 shares of common stock, par value $0.01 per share, that may be issued under the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the &#8220;2026 Plan&#8221;) that became effective May 13, 2026 (the &#8220;Effective Date&#8221;). The maximum number of shares that may be issued under the 2026 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2026 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares that may be subject to grant or otherwise issuable after the operation of any such anti-dilution provisions, stock splits, or other similar transactions.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant&#8217;s common stock on the Nasdaq Global Select Market on May 8, 2026.</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th" colspan="2">
<div>May 13, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 2,729,792,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">376,984.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 376,984.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant&#8217;s common stock on the Nasdaq Global Select Market on May 8, 2026.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>20</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="exfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="exfilingfees.htm">exfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/ffd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "exfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
     ]
    }
   },
   "keyStandard": 20,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/ffd/2026": 3,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2026": 18,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ffd:FormTp",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ffd:SubmissnTp",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ffd:FormTp",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ffd:SubmissnTp",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ffd:FeesOthrRuleFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ffd:FeesOthrRuleFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal8ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000875320-26-000206-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875320-26-000206-xbrl.zip
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MP?*ID0SO+($D?:)9,E1^%_I:R-?;\-\RY1]+_K'EGYK\4_\&XNV2>'L6Y\O
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MSBW9P$'S/W?^NP&5?E/.*T219(#7]JV*Z75X1YX)YS8.5!T!<GT%;O$3+38
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3!@     !  $ /@   +,+      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>exfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875320</identifier>
        </entity>
        <period>
            <startDate>2026-05-13</startDate>
            <endDate>2026-05-13</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875320</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-13</startDate>
            <endDate>2026-05-13</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-16">0000875320</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="c-1" id="f-17">VERTEX PHARMACEUTICALS INC / MA</dei:EntityRegistrantName>
    <ffd:FeeExhibitTp contextRef="c-1" id="f-18">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:PrevslyPdFlg contextRef="c-2" id="f-19">false</ffd:PrevslyPdFlg>
    <ffd:OffsetTableNa contextRef="c-1" id="f-20">N/A</ffd:OffsetTableNa>
    <ffd:SubmissnTp contextRef="c-1" id="f-1">S-8</ffd:SubmissnTp>
    <ffd:FormTp contextRef="c-1" id="f-2">S-8</ffd:FormTp>
    <ffd:OfferingSctyTp contextRef="c-2" id="f-3">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c-2" id="f-4">Common stock, $0.01 par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c-2" id="f-5">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd contextRef="c-2" decimals="0" id="f-6" unitRef="shares">6400000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c-2"
      decimals="2"
      id="f-7"
      unitRef="usdPerShare">426.53</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric contextRef="c-2" decimals="0" id="f-8" unitRef="usd">2729792000</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c-2" decimals="7" id="f-9" unitRef="number">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c-2" decimals="2" id="f-10" unitRef="usd">376984.28</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="c-1" decimals="0" id="f-11" unitRef="usd">2729792000</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="c-1" decimals="2" id="f-12" unitRef="usd">376984.28</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="c-1" decimals="2" id="f-13" unitRef="usd">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="c-1" decimals="2" id="f-14" unitRef="usd">376984.28</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c-2" id="f-15">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant&#x2019;s common stock on the Nasdaq Global Select Market on May 8, 2026.&lt;/span&gt;&lt;/div&gt;</ffd:OfferingNote>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#f-6" xlink:label="f-6" xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Consists of 6,400,000 shares of common stock, par value $0.01 per share, that may be issued under the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the &#x201c;2026 Plan&#x201d;) that became effective May 13, 2026 (the &#x201c;Effective Date&#x201d;). The maximum number of shares that may be issued under the 2026 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2026 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares that may be subject to grant or otherwise issuable after the operation of any such anti-dilution provisions, stock splits, or other similar transactions.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-6"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc xlink:href="#f-7" xlink:label="f-7" xlink:type="locator"/>
        <link:loc xlink:href="#f-11" xlink:label="f-11" xlink:type="locator"/>
        <link:loc xlink:href="#f-14" xlink:label="f-14" xlink:type="locator"/>
        <link:loc xlink:href="#f-8" xlink:label="f-8" xlink:type="locator"/>
        <link:loc xlink:href="#f-10" xlink:label="f-10" xlink:type="locator"/>
        <link:loc xlink:href="#f-13" xlink:label="f-13" xlink:type="locator"/>
        <link:loc xlink:href="#f-12" xlink:label="f-12" xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant&#x2019;s common stock on the Nasdaq Global Select Market on May 8, 2026.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-7"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-11"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-14"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-8"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-10"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-13"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-12"
          xlink:to="fn-2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
